Foreign Clinical Trial Oversight: FDA Must Ensure “System Is Not Broken”
This article was originally published in The Gray Sheet
Executive Summary
FDA will need to rely on overseas regulatory agencies to ensure the quality of foreign clinical trials in order to devote more resources to inspections in countries with less infrastructure, according to the agency